Diabetes, Vol 46, Issue 2 292-300, Copyright © 1997 by American Diabetes Association

ARTICLES

Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury

R Ramasamy, PJ Oates and S Schaefer
Department of Internal Medicine, University of California, Davis 95616, USA.

Diabetes increases the incidence of cardiovascular disease as well as the complications of myocardial infarction. Studies using animal models of diabetes have demonstrated that the metabolic alterations occurring at the myocyte level may contribute to the severity of ischemic injury in diabetic hearts. Of the several mechanisms being investigated to understand the pathogenesis of diabetic complications, the increased metabolism of glucose via the polyol pathway has received considerable attention. Deviant metabolic regulation due to increased flux through aldose reductase in diabetic hearts may influence the ability of the myocardium to withstand ischemia insult. To determine if aldose reductase inhibition improves tolerance to ischemia, hearts from acute type I diabetic and nondiabetic control rats were isolated and retrograde perfused. Each group was exposed to 1 micromol/l zopolrestat, a specific inhibitor of aldose reductase, for 10 min, followed by 20 min of global ischemia and 60 min of reperfusion in the absence of zopolrestat. Zopolrestat reduced sorbitol levels before ischemia in diabetic hearts. The cytosolic redox state (NADH/NAD+), as measured by lactate-to-pyruvate ratios, was significantly lowered under baseline, ischemic, and reperfusion conditions in diabetic hearts perfused with zopolrestat. In these diabetic hearts, ATP was significantly higher in zopolrestat hearts during ischemia, as were phosphocreatine and left ventricular-developed pressure on reperfusion. Zopolrestat provided similar metabolic and functional benefits in nondiabetic hearts. Creatine kinase release was reduced by approximately 50% in both nondiabetic and diabetic hearts treated with zopolrestat. These data indicate that inhibition of aldose reductase activity preserves high-energy phosphates, maintains a lower cytosolic NADH/NAD+ ratio, and markedly protects both diabetic and nondiabetic hearts during ischemia and reperfusion.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. An and B. Rodrigues Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1489 - H1506. [Abstract] [Full Text] [PDF]

				I. J. Goldberg and H. M. Dansky Diabetic Vascular Disease: An Experimental Objective Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1693 - 1701. [Abstract] [Full Text] [PDF]

				K. Kaiserova, S. Srivastava, J. D. Hoetker, S. O. Awe, X.-L. Tang, J. Cai, and A. Bhatnagar Redox Activation of Aldose Reductase in the Ischemic Heart J. Biol. Chem., June 2, 2006; 281(22): 15110 - 15120. [Abstract] [Full Text] [PDF]

				R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation Glycobiology, July 1, 2005; 15(7): 16R - 28R. [Abstract] [Full Text] [PDF]

				S. K. Srivastava, K. V. Ramana, and A. Bhatnagar Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options Endocr. Rev., May 1, 2005; 26(3): 380 - 392. [Abstract] [Full Text] [PDF]

				J. R. Nyengaard, Y. Ido, C. Kilo, and J. R. Williamson Interactions Between Hyperglycemia and Hypoxia: Implications for Diabetic Retinopathy Diabetes, November 1, 2004; 53(11): 2931 - 2938. [Abstract] [Full Text] [PDF]

				Y. C. HWANG, M. KANEKO, S. BAKR, H. LIAO, Y. LU, E. R. LEWIS, S. YAN, S. II, M. ITAKURA, L. RUI, et al. Central role for aldose reductase pathway in myocardial ischemic injury FASEB J, August 1, 2004; 18(11): 1192 - 1199. [Abstract] [Full Text] [PDF]

				R. Ramasamy, Y. C. Hwang, Y. Liu, N. H. Son, N. Ma, J. Parkinson, R. Sciacca, A. Albala, N. Edwards, M. J. Szabolcs, et al. Metabolic and Functional Protection by Selective Inhibition of Nitric Oxide Synthase 2 During Ischemia-Reperfusion in Isolated Perfused Hearts Circulation, April 6, 2004; 109(13): 1668 - 1673. [Abstract] [Full Text] [PDF]

				S. F. Yan, R. Ramasamy, Y. Naka, and A. M. Schmidt Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond Circ. Res., December 12, 2003; 93(12): 1159 - 1169. [Abstract] [Full Text] [PDF]

				A. S. Galvez, J. A. Ulloa, M. Chiong, A. Criollo, V. Eisner, L. F. Barros, and S. Lavandero Aldose Reductase Induced by Hyperosmotic Stress Mediates Cardiomyocyte Apoptosis: DIFFERENTIAL EFFECTS OF SORBITOL AND MANNITOL J. Biol. Chem., October 3, 2003; 278(40): 38484 - 38494. [Abstract] [Full Text] [PDF]

				K. Shinmura, R. Bolli, S.-Q. Liu, X.-L. Tang, E. Kodani, Y.-t. Xuan, S. Srivastava, and A. Bhatnagar Aldose Reductase Is an Obligatory Mediator of the Late Phase of Ischemic Preconditioning Circ. Res., August 9, 2002; 91(3): 240 - 246. [Abstract] [Full Text] [PDF]

				J. C. Chatham, C. Des Rosiers, and J. R. Forder Evidence of separate pathways for lactate uptake and release by the perfused rat heart Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E794 - E802. [Abstract] [Full Text] [PDF]

				R. Ramasamy, J. A. Payne, J. Whang, S. R. Bergmann, and S. Schaefer Protection of ischemic myocardium in diabetics by inhibition of electroneutral Na+-K+-2Cl{-} cotransporter Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H515 - H522. [Abstract] [Full Text] [PDF]

				R. Ramasamy, Y. C. Hwang, J. Whang, and S. R. Bergmann Protection of ischemic hearts by high glucose is mediated, in part, by GLUT-4 Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H290 - H297. [Abstract] [Full Text] [PDF]

				W. R. Tracey, W. P. Magee, C. A. Ellery, J. T. MacAndrew, A. H. Smith, D. R. Knight, and P. J. Oates Aldose reductase inhibition alone or combined with an adenosine A3 agonist reduces ischemic myocardial injury Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1447 - H1452. [Abstract] [Full Text] [PDF]

				N. A. Trueblood, R. Ramasamy, L. F. Wang, and S. Schaefer Niacin protects the isolated heart from ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H764 - H771. [Abstract] [Full Text] [PDF]

				B. Isermann, S. Schmidt, A. Bierhaus, S. Schiekofer, V. Borcea, R. Ziegler, P. P. Nawroth, and E. Ritz (CA)n Dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1 Nephrol. Dial. Transplant., June 1, 2000; 15(6): 918 - 920. [Full Text] [PDF]

				I. M. Kapetanovic, C. D. Torchin, C. D. Thompson, T. A. Miller, P. J. McNeilly, T. L. Macdonald, H. J. Kupferberg, J. L. Perhach, R. D. Sofia, and J. M. Strong Potentially Reactive Cyclic Carbamate Metabolite of the Antiepileptic Drug Felbamate Produced by Human Liver Tissue In Vitro Drug Metab. Dispos., November 1, 1998; 26(11): 1089 - 1095. [Abstract] [Full Text]

				N. Trueblood and R. Ramasamy Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H75 - H83. [Abstract] [Full Text] [PDF]

				R. Ramasamy, N. Trueblood, and S. Schaefer Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H195 - H203. [Abstract] [Full Text] [PDF]